Skip to main content

Advertisement

SpringerLink
Log in

Cytotoxicity of Cord Blood Derived Her2/neu-specific Cytotoxic T Lymphocytes against Human Breast Cancer in vitro and in vivo

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

The Her2/neu oncogene encodes a transmembrane protein with homology to the epidermal growth factor receptor. Overexpression of this gene contributes to the aggressiveness of breast cancer and poor prognosis. Therefore, Her2/neu is an ideal target molecule for generating effective cytotoxic T lymphocytes (CTLs) against breast cancers. This study reports on the generation of Her2/neu-specific CTL from umbilical cord blood mononuclear cells (UCBC) using dendritic cells primed with Her2/neu-derived peptide (KIFGSLAFL, E75) for immunostimulation. The CTLs showed specific cytotoxicity to Her2/neu high expressing MDA-453 but not toward Her2/neu low expressing MDA-231 human breast cancer cells. Similarly generated CTLs stimulated with irrelevant peptide pulsed dendritic cells did not show significant cytotoxicity towards breast cancer targets. The phenotypes of cells in culture showed high percentage of CD3+, CD4+ and CD8+T cells as determined by flow cytometry. However, the antibody mediated blocking assay demonstrated that only HLA-Class I restricted CD8+ cells are involved in the cytotoxicity. Furthermore, in vivo studies showed that treatment of SCID mice bearing MDA-453 tumor with Her2/neu-specific CTLs resulted in significant inhibition of tumor growth compared to untreated tumor bearing control mice. These results demonstrate that human umbilical cord blood mononuclear cells are a good source for generating Her2/neu-specific CTLs against human breast cancer both in vitro and in vivo.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. McPherson K, Steel CM, Dixon JM: ABHC of breast diseases. Breast cancer epidemiology, risk factors, and genetics. BrMed J 321: 624–628, 2000

    Google Scholar 

  2. Esteva FJ, Valero V, Pusztai L, Boehnke-Michaud L, Buzdar AU, Hortobagyi GN: Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. Oncologist 6: 133–146, 2001

    Google Scholar 

  3. Kim R, Tanabe K, Uchida Y, Osaki A, Toge T: The role of Her2 oncoprotein in drug-sensitivity in breast cancer (review). Oncol Rep 9: 3–9, 2002

    Google Scholar 

  4. Eccles SA: The role of c-erb-2/Her2/neu in breast cancer progression and metastasis. J Mammary Gland Biol Neoplasia 6: 393–406, 2001

    Google Scholar 

  5. Rahman ZU, Hortobagyi GN, Buzdar AU, Champlin R: High-dose chemotherapy with autologous stem cell support in patients with breast cancer. Cancer Treat Rev 24: 249–263, 1998

    Google Scholar 

  6. Buzdar AU, Hortobagyi GN: Breast cancer. Cancer Chemother Biol Response Modif 18: 435–469, 1999

    Google Scholar 

  7. Wang SC, Zhang L, Hortobagyi GN, Hung MC: Targeting HER2: recent developments and future directions for breast cancer patients. Semin Oncol 28: 21–29, 2001

    Google Scholar 

  8. zum Buschenfelde CM, Hermann C, Schmidt B, Peschel C, Bernhard H: Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells. Cancer Res 15: 2244–2247, 2002

    Google Scholar 

  9. Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, Baselga J, Shao Y, Nielsen UB, Marks JD, Moore D, Papahadjopoulos D, Benz CC: Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res 8: 1172–1181, 2002

    Google Scholar 

  10. Eibl B, Schwaighofer H, Nachbaur D, Martin C, Gachter A, Knapp R, Bock G, Gasner C, Nederwiser D: Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 88: 1501–1508, 1996

    Google Scholar 

  11. Levitt SH, Kennedy A: Adjuvant therapy of breast cancer - an overview. Acta Oncol 37: 403–409, 1998

    Google Scholar 

  12. Apperley JF: Umbilical cord blood progenitor cell transplantaion. Bone Marrow Transplant 14: 187–196, 1994

    Google Scholar 

  13. Cairo MS, Wagner JE: Placental and/or umbilical cord blood: an alternative source of hematopoietic stem cells for transplantation. Blood 90: 4665–4678, 1997

    Google Scholar 

  14. Gluckman E, Broxmeyer H, Auerbach AD, Friedman HS, Douglas GW, Devergie A, Esperou H, Thierry D, Socie G, Lehn P, Bard J, Boyse ES: Hematopoietic reconstitution in a patient with Fancini's anemia by means of umbilical cord blood from an HLA-identical sibling. N Engl J Med 321: 1174–1178, 1989

    Google Scholar 

  15. Harris DT, Schumacher MJ, LoCascio J, Booth A, Bard J, Boyse EA: Immunoreactivity of umbilical cord blood and post-partum maternal peripheral blood with regard to HLA-haploidentical transplantation. Bone Marrow Transplant 14: 63–68, 1994

    Google Scholar 

  16. Harris DT: In vitro and in vivo assessment of the graft-versus-leukemia activity of cord blood. Bone Marrow Transplant 15: 17–23, 1995

    Google Scholar 

  17. Joshi SS, Babushkina-Patz NN, Verbik DJ, Gross TG, Tarantolo SR, Kuszynki CA, Pirruccello SJ, Bishop MR, Kessinger A: Antitumor activity of human umbilical cord blood cells: A comparative analysis with peripheral blood and bone marrow cells. Int J Oncol 13: 791–799, 1998

    Google Scholar 

  18. Joshi SS, Tarantolo SR, Kuszynski CA, Kessinger A: Antitumor therapeutic potential of activated human umbilical cord blood against leukemia and breast cancer. Clin Can Res 6: 4351–4358, 2000

    Google Scholar 

  19. Verbik DJ, Jackson JD, Pirruccello SJ, Patil KD, Kessinger A, Joshi SS: Functional and phenotypic characterization of human peripheral blood stem cell harvests: a comparative analysis of cells from consecutive collections. Blood 85: 1964–1970, 1995

    Google Scholar 

  20. Kessinger A, Armitage JO: Editorial: the evolving role of autologous peripheral stem cell transplantation following high dose therapy for malignancies. Blood 77: 211–213, 1991

    Google Scholar 

  21. Pirruccello SJ, Jackson JD, Sharp JG: Leukemic myeloid cell line OMA-AML-1: an in vitro model of hematopoietic cell differentiation. Leuk Lymphoma 13: 169–178, 1997

    Google Scholar 

  22. Joshi SS, Vu UE, Lovgren TR, Lorkovic M, Patel W, Todd GL, Kuszynski C, Joshi BJ: Comparison of phenotypic and functional dendritic cells derived from human umbilical cord blood and peripheral blood mononuclear cells. J Hema Stem Cell Re: 337–347, 2002

  23. Brossart P, Stuhler G, Flad T, Stevanovic S, Rammensee HG, Kanz L, Brugger W: Her2/neu-derived peptides are tumor-associated antigen expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res 15: 732–738, 1998

    Google Scholar 

  24. Sarkar AK, Nuchtern JD: Lysis of MYCN-amplified neuroblastoma cells by MYCN peptide-specific cytotoxic T lymphocytes. Cancer Res 60: 1908–1913, 2000

    Google Scholar 

  25. Broxmeyer HE, Gluckman E, Auerbach AD, Douglas GW, Friedman H, Cooper S, Hangoc G, Kurtzberg J, Bard J, Boyse EA: Human umbilical cord blood: a clinically useful source of transplantable hematopoietic stem/progenitor cells. Int J Cell Cloning 8: 76–84, 1990

    Google Scholar 

  26. Hayes DF, Thor AD: c-erbB-2 in breast cancer: development of a clinically useful marker. Semin Oncol 29: 231–245, 2002

    Google Scholar 

  27. Eccles SA: The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis. J Mammary Gland Biol Neoplasia 6: 393–406, 2001

    Google Scholar 

  28. Lohrisch C, Piccart M: HER2/neu as a predictive factor in breast cancer. Clin Breast Cancer 2: 129–135, 2001

    Google Scholar 

  29. Rilke F, Colnaghi MI, Cascineli N, Andreola S, Baldini MT, Testori A: Prognostic significance of Her2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer 49: 44–49, 1991

    Google Scholar 

  30. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the Her2/neu oncogene. Science 235: 177–182, 1987

    Google Scholar 

  31. Coveney E, Wheatley III GH, Lyerly HK: Active immunization using dendritic cells mixed with tumor cells inhibits the growth of primary breast cancer. Surgery 122: 228–234, 1997

    Google Scholar 

  32. Soda H, Koda K, Yasutomi J, Oda K, Takiguchi N, Saito N, Nakajima N: Adoptive immunotherapy for advanced cancer patients using in vitro activated cytotoxic T lymphocytes. J Sury Oncol 72: 211–217, 1999

    Google Scholar 

  33. Verbik DJ, Joshi SS: Immune cells and cytokines: their role in cancer immunotherapy. Int J Oncol 7: 205–223, 1995

    Google Scholar 

  34. Michalevicz R, Shlafstein M, Sheridan AP: Highly purified hematopoietic progenitors from cord blood: response to mMGF (KIT-LIGAND), IL-3, IL-1, and GM-CSF. Blood 78: 22a, 1991

    Google Scholar 

  35. Piacibello W, Ferroro D, Sanavio F, Badoni R, Stacchini A, Severino A, Aglietta M: Responsiveness of highly enriched CFU-GM subpopulations from bone marrow, peripheral blood, and cord blood to hematopoietic growth inhibitors. Exp Hematol 19: 1084–1089, 1991

    Google Scholar 

  36. Gardner JD, Liechty KW, Christinsen RD: Effects of interleukin-6 on fetal hematopoietic progenitors. Blood 75:2150–2155, 1990

    Google Scholar 

  37. Wagner JE, Broxmeyer HE, Byrd RL, Zehnbauer B, Schmeckpeper B, Shah N, Griffin C, Emanuel PD, Zuckeman KS, Cooper S, Carow C, Bias W, Santos G: Transplantation of umbilical cord blood after myeloablative therapy: analysis of engraftment. Blood 79: 1874–1881, 1995

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Genetics, Cell Biology and Anatomy, University of Nebraska Medical Center, Omaha, NE, USA

    Peng Wang, Corey M. Munger, Avadhut D. Joshi, Samuel J. Pirruccello & Shantaram S. Joshi

Authors
  1. Peng Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Corey M. Munger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Avadhut D. Joshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Samuel J. Pirruccello
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shantaram S. Joshi
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wang, P., Munger, C.M., Joshi, A.D. et al. Cytotoxicity of Cord Blood Derived Her2/neu-specific Cytotoxic T Lymphocytes against Human Breast Cancer in vitro and in vivo. Breast Cancer Res Treat 83, 15–23 (2004). https://doi.org/10.1023/B:BREA.0000010688.55353.a8

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:BREA.0000010688.55353.a8

Search

Navigation